Tyrosine kinases play key roles in cell proliferation, survival and differentiation. Their aberrant activation, caused either by the formation of fusion genes by chromosome translocation or by intragenic changes, such as point mutations or internal duplications, is of major importance in the development of many haematological malignancies. An understanding of the mechanisms by which BCR-ABL contributes to the pathogenesis of chronic myeloid leukaemia led to the development of imatinib, the first of several tyrosine kinase inhibitors to enter clinical trials. Although the development of resistance has been problematic, particularly in aggressive disease, the development of novel inhibitors and combination with other forms of therapy shows promise.
Skip Nav Destination
Article navigation
October 2006
-
Cover Image
Cover Image
- PDF Icon PDF LinkTable of Contents
Review Article|
September 13 2006
Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases Available to Purchase
Andrew Chase;
Andrew Chase
1Wessex Regional Genetics Laboratory, Salisbury and Human Genetics Division, University of Southampton, Salisbury District Hospital, Salisbury SP2 8BJ, U.K.
Search for other works by this author on:
Nicholas C. P. Cross
1Wessex Regional Genetics Laboratory, Salisbury and Human Genetics Division, University of Southampton, Salisbury District Hospital, Salisbury SP2 8BJ, U.K.
Correspondence: Professor Nicholas C. P. Cross (email [email protected]).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
February 10 2006
Revision Received:
March 31 2006
Accepted:
April 03 2006
Online ISSN: 1470-8736
Print ISSN: 0143-5221
The Biochemical Society
2006
Clin Sci (Lond) (2006) 111 (4): 233–249.
Article history
Received:
February 10 2006
Revision Received:
March 31 2006
Accepted:
April 03 2006
Citation
Andrew Chase, Nicholas C. P. Cross; Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases. Clin Sci (Lond) 1 October 2006; 111 (4): 233–249. doi: https://doi.org/10.1042/CS20060035
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |